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Abstract  
BACKGROUND: Clear cell renal cell carcinoma (CCRCC) is the most predominant renal tumour with 
unpredictable tumour behaviour. The aim of the study is to investigate the prognostic value of vascular endothelial 
growth factor A (VEGF-A) expression in CCRCC and to correlate it with other histological parameters as well as 
with patient's survival.
 
MATERIAL AND METHODS: Tumour blocks were taken from 40 patients with histopathology diagnosis of 
CCRCC and tissue block from 20 normal kidneys as a control group were examined using the immuno-
histochemical staining for VEGF-A. 
 
RESULTS: The VEGF A expression in CCRCC was significantly higher than in the normal kidney tissues (U’ = 
720, P < 0.0001). VEGF A expression values in CCRCC were positively correlated with Disease Free Survival (r = 
0.335, P = 0.034) and the tumor necrosis degree (r = 0.181, P = 0.262). VEGF-A expression values in CCRCC 
did not correlate with CD 31 expression (r = -0.09, P = 0.549), and Progression Free Survival (r = -0.07, P = 
0.838). VEGF A expression values in CCRCC were negatively correlated with the tumor nuclear grade (r = -0.161, 
P = 0.318); the pathological tumor stage (r = -0.371, P = 0.018); the tumor size (r = -0.361, P = 0.022); the degree 
of tumor hemorrhage (r = -0.235, P = 0.143); and Cancer Specific Survival   (r = -0.207, P = 0.713). 
CONCLUSIONS: VEGF-A expression can be used to stratify advanced and metastatic CCRCC patients into low-
benefit and high-benefit groups. Based on this study outcome it would be useful to perform IHC staining for 
VEGF-A expression in all patients with advanced and metastatic CCRCC. 
 
 
 
 
 
 
 
Introduction 
 
  Renal cell carcinomas (RCCs) are the 
seventh most common histological type of cancer in 
the Western world and have maintained an increasing 
prevalence, representing 1% to 3% of all malignant 
visceral neoplasms [1]. The mortality incidence ratio is 
higher in RCC than in other urological malignancies 
[2]. RCC has been reported to be resistant to radiation 
or chemotherapy, and the prognosis for these patients 
remains poor [3]. Histopathological evaluations of 
RCC have revealed that highly vascularized neoplasm 
is demonstrating clear evidence of abundant 
angiogenesis and abnormal blood vessel 
development [4]. This notion has thus raised 
considerable concerns regarding the development of 
agio suppressive therapies for RCC.  Until now, many 
angiogenic molecules have been identified [5].  
Vascular endothelial growth factor (VEGF) is a potent 
endothelial cell mitogen and is an important 
component of the angiogenic stimulus in a range of 
human neoplasias [6]. VEGF is a multifunctional 
cytokine that can increase microvascular permeability 
[7] and stimulate endothelial cell growth and 
angiogenesis [8]. Several factors can influence VEGF 
expression, including hypoxia [9] and transform 
growth factor-β [10]. Once VEGF binds to VEGF 
receptors, receptor dimerization and autophosph-
orylation are induced and downstream signalling via 
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several secondary messengers, including several 
protein kinases and phosphatases, are activated. This 
supports a proangiogenic phenotype [11]. 
 The aim of the study is to investigate the 
prognostic value of VEGF-A expression in Clear cell 
renal cell carcinoma (CCRCC) and to correlate it with 
other histological parameters as well as with patient's 
survival rate. 
 
 
 
Materials and Methods 
 
  Patients 
The study included a total of 40 patients with 
histopathologically verified RCC after surgery in the 
period between January 2008 and July 2014. Before 
surgery, all patients signed an informed consent form. 
This research was approved by the ethics committee 
at the Medical Faculty - Prishtina University.  There 
were 19 men and 21 women, with a median age of 
60.3 years (range 36 – 81 years). Among 40 patients, 
32 patients undergone nephrectomy, seven partial 
nephrectomies (NSS), and one bilateral radical 
nephrectomy due to bilateral RCC. None of the 
patients had been treated with radiation, 
chemotherapy, or immunotherapy before surgery. 
Most of the patients were followed-up using clinical 
and radiological examinations at regular intervals. 
Survival was determined from the nephrectomy time 
to the latest follow-up. At the latest follow-up, 33 
patients were alive with a median follow-up time of 26 
months, (range 2 – 72 months),  6 of them died of 
RCC with a median survival rate of 9 months (range 2 
– 24 months), and one patient died of unrelated 
causes  10 months after nephrectomy. 
 
The control group included tissue sections of 
normal kidneys from 20 cases provided by forensic 
autopsies at the Department of Forensic Pathology in 
Prishtina, Kosovo. 
 
Morphological grading  
 
Histopathological nuclear grading has been 
performed by pathologists in the Institute of 
Pathology, University Clinical Center of Kosovo, 
based on the worse histological features, according to 
Fuhrman and co-workers [12]. As a result, 25 (62.5 %) 
cases were classified as Fuhrman grade 2; 13 (32.5 
%) cases as Fuhrman grade 3, and 2 (5.0 %) cases 
as Fuhrman grade 4.  Nuclear grade was assessed by 
combining nuclear grades 1 and 2 into one group, and 
nuclear grades 3 and 4 as another group.  
 
 
Tumor staging 
The tumour stage has been determined by 
TNM classification system 2010 [13]. This 
classification system has been used to evaluate the 
tumour size, the status of the regional lymph nodes 
and the perinephric tissue, and tumour invasion 
through the renal capsule into perirenal fat or major 
renal veins at the renal hilum. There have been 
identified 17 cases of stage I (42.5%), 8 cases of 
stage II (20.0 %), 12 cases of stage III (30.0 %), and 3 
cases of stage IV (7.5%). The tumour size has been 
measured as the maximal diameter of the tumour 
mass. The median tumour diameter was 71.0 mm 
(range 13-125 mm).
 
 
Tissue collection and preparation 
Tumour and kidney cortex tissue samples 
were obtained from the surgical specimen. Each 
sample was divided into smaller pieces (1-2 cm^2). 
Samples were formalin fixed and paraffin embedded 
for immuno-histochemical staining and morphologic 
examination. 
 
Immunohistochemestry 
Representative paraffin tumour blocks were 
selected by primary evaluation of haematoxylin/eosin-
stained slides. For immunohistochemical evaluation 4-
μm, thick paraffin blocks were sliced. Slides were 
treated with standard procedures of deparaffinisation, 
rehydration, microwave heating and immuno-
histochemical (IHC) staining. For the IHC techniques, 
the antibodies VEGF-A (A-20, 1:150 dilution; Santa 
Cruz Biotechnology Inc, CA, USA) were used.  
IHC results were independently evaluated by 
two specialised pathologists, blinded to each patient's 
clinical data. VEGF-A protein expression mainly was 
observed in the cytoplasm of the tumour cells. IHC 
VEGF-An expression was quantified by estimating the 
volume density and staining intensity on a three-grade 
scale. A semiquantitative scoring system was used, 
based on staining intensity (0, negative; 1, weak; 2, 
intermediate; 3, strong), which was corresponded to 
the percentage of positive stained cells (0, 0%; 1, < 
25% positive; 2, 26-50% positive; 3, ≥ 50% positive)  
[14].  
The positive and uniform IHC VEGF-A 
expressions in normal kidney tubular cells were used 
as a control for immuno-histochemical evaluation of 
positive IHC VEGF-An expression in tumour cells. 
 
Microvessel counting was used for 
angiogenesis assessment. Immunostained tumour 
sections were scanned at high power magnification 
(200 x) to identify the areas with highest vascular 
density so-called "hot -spots". Determining 
microvessel density was expressed as the number of 
stained microvessels per optical field. Any cell or cell 
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cluster showing positive CD31 staining was counted 
as a vessel, as described in the Weidner method [15].  
The degree of necrosis and degree of 
haemorrhage has been assessed with the presence 
versus absence of haemorrhage and necrosis.
 
  
Statistical methods 
The Mann-Whitney U test was used to identify 
differences in not-parametric variables for two 
independent groups, and the Kruskal-Wallis test was 
used for comparison of more than two groups. 
Spearman rank correlation test was used to compare 
the relationship between sets of non-parametric 
variables that did not demonstrate a linear relation. 
Chi-Square test was used to evaluate differences in 
proportions of observations between independent 
groups. Fisher's exact test was used when the sample 
size was too small to use the chi-square test. The 
median value was chosen as the cut-off value. 
Survival data was analysed using the Kaplan-Meier 
method, and comparison of survival times for groups 
was performed with the log-rank test. The variables 
were dichotomously tested and analysed as 
continuous in a univariate Cox regression analysis. 
Survival time was measured from the date of 
nephrectomy to the date of death or latest follow-up. 
In all tests, a two-tailed significance level was set to < 
0.05.  
 
 
Results 
 
Immunohistochemical assessment of 
VEGF-A expression
 
In normal renal tissues, VEGF-A expression 
was limited to the cytoplasm of tubular epithelium, 
smooth muscle cells and macrophages in the 
interstitial tissue, and mesangial cells in the glomerule 
(Fig. 1).  
 
Figure 1: IHC staining of VEGF-A in control group (200 x)
 
In CCRCC, VEGF-A was expressed in the 
cytoplasm of tumour cells, endothelial cells, and 
stromal ﬁbroblasts (Fig. 2). 
 
Figure 2: IHC staining of VEGF-A in CCRCC
 
 
The average value of VEGF-A expression in 
CCRCCs group was 2.75 (DS ± 0.44), and 1.8 (DS ± 
0.41) in the control group. The study provided a 
difference with an important statistical significance 
between VEGF-A expression in CCRCC group and 
non-malignant kidney tissues group (U' = 720, P < 
0.0001). No significant difference has been recorded 
for the values of VEGF-A between both genders (U' = 
224.5, P = 0.494). Using Kruskal-Wallis test no 
difference with an important statistical significance 
between VEGF-A values regarding tumour size was 
detected (KW = 6.06, P = 0.048) (Table 1).   
Table 1: Results of VEGF expression in CCRCC according to 
study groups, genders and tumour size
 
Characteristics VEGF-An expression
 
Study groups  
Control 1.80 (SD ± 0.41) 
CCRCC 2.75 (SD ± 0.44) 
Sex  
Male 2.68 (SD ± 0.48) 
Female 2.81 (SD ± 0.40) 
Tumor size  
< 40 mm 2.80 (SD ± 0.45) 
40-70 mm 2.90 (SD ± 0.31) 
>70 mm 2.53 (SD ± 0.52) 
 
 
The average value of VEGF-A expression in 
patients with CCRCC nuclear grade 2 was 2.80 (DS ± 
0.41), while in patients with CCRCC nuclear grade 3 
and 4 was 2.67 (DS ± 0.49). The statistical analysis 
showed no difference between VEGF-A values and 
the tumour nuclear grade (U' = 212.5, P = 0.484). The 
average value of VEGF-A expression in patients with 
CCRCC pathological stage I and II was 2.88 (DS ± 
0.33), while in patients with CCRCC pathological 
stage III and IV was 2.53 (DS ± 0.52). Additionally no 
difference between VEGF-A values regarding the 
tumor stage was recorded (U' = 252.5, P = 0.067).  
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Correlations between VEGF A and other 
clinicopathologic parameters 
VEGF A expression values in CCRCC was 
positively correlated with Disease free survival (DFS) 
(r = 0.335, P = 0.034) and the tumor necrosis degree 
(r = 0.181, P = 0.262). VEGF A expression values in 
CCRCC was not correlated with CD 31 expression (r= 
-0.09, P = 0.549) and Progression free survival (PFS) 
(r = -0.07, P=0.838). 
Table 2: Correlations between VEGF A expression and other 
prognostic factors 
Clinicopathologic parameters VEGF-A 
Tumor size r = -0.361 
Tumor hemorrhage r = -0.235 
Tumor necrosis r = 0.181 
Nuclear grade r = -0.161 
Pathological stage r = -0.371 
CD 31  r = -0.090 
DFS r = 0.335 
PFS r = -0.070 
CSS r = -0.207 
 
VEGF A expression values in CCRCC were 
negatively correlated with the tumor nuclear grade (r = 
-0.161, P = 0.318), the pathological tumor stage (r = -
0.371, P = 0.018), the tumor size (r = -0.361, P = 
0.022), tumor hemorrhage degree (r = -0.235, P = 
0.143), Cancer specific survival (CSS) (r = -0.207, 
P=0.713) (Table 2). 
  
 
Discussion 
 
Angiogenesis is controlled by angiogenic 
factors that regulate extracellular matrix remodelling, 
endothelial cell proliferation, capillary differentiation, 
and anastomosis necessary to establish a blood 
supply. Angiogenic stimuli are released by tumour 
cells, stromal cells, and inflammatory cells recruited to 
the tumour site [16]. Among several identified 
peptides with angiogenic properties, the vascular 
endothelial growth factor (VEGF) is thought to play a 
major role in tumour angiogenesis [17]. Tumour 
angiogenesis has been well documented both in 
experimental and clinical studies, and the degree of 
angiogenesis was closely associated with tumour 
progression and shorter patient survival in many types 
of cancers [18], whereas data for RCC are 
controversial [19].  
The results showed that the VEGF-A 
expression in patients with CCRCC was higher than in 
normal kidney tissues. Despite other studies in which 
the control group consisted of non-tumorous tissue 
from the surrounding of the tumour, the control group 
of our study included normal kidney tissues provided 
by the forensic autopsies. Given that VEGF-A 
expression was higher in CCRCC, it could be 
postulated that VEGF-A expression might have an 
effect on the non-tumorous tissue of the same kidney 
making such control group unreliable for comparison. 
On the other hand, the control tissues of this study did 
not show pathological changes and therefore can be 
deemed more credible.
 
In the current research, VEGF-A expression 
in CCRCC was positively correlated with the tumor 
necrosis degree (r = 0.181, P = 0.262).  In Rioux-
Leclercq N [20] study, VEGF expression was also 
correlated with tumour necrosis (P = 0.001). Based on 
IHC data, several investigators have reported that 
VEGF overexpression in CCRCC was associated with 
tumour stage, pathological grade, histological vein 
invasion and prognosis [21, 22]. Tumour angiogenesis 
was reported to be the only significant predictor of 
prognosis in low stage RCC [23]. However, 
angiogenesis was not related to the tumour 
malignancy or patient survival of RCC [24]. Verheul et 
al. reported that VEGF expression using IHC in 
CCRCC was not significantly correlated with 
prognosis [25].  
An important finding of our study was that 
VEGF-A expression is significantly correlated with 
prognosis.  This discrepancy in IHC results could be 
due to several factors including differences in fixation, 
scoring and staining methods [25-27].  
Compared to other studies, our approach was 
to comprehend different factors such as the tumour 
grade and stage with macroscopic features such as 
tumour size, haemorrhage degree and tumour 
necrosis degree. Our study showed a decrease in 
VEGF-A expression in more advanced tumour grade 
and stage and large tumour sizes. Although not 
statistically  significant, the study results showed that 
higher VEGF expression is a good prognostic factor 
for low pathologic tumour stage CCRCCs,  similarly to 
that described in the study of Nativ  et al. [23]. 
 
Our study showed a positive correlation 
between VEGF-A expression tumour necrosis degree 
and a negative correlation between VEGF-A 
expression and tumour haemorrhage degree. Minardi 
et al. in his study could not find a correlation between 
the endothelial and tumoral cells cytoplasmic 
expression of VEGF and tumour necrosis [26].
 
Also, a correlation between VEGF-A 
expression and Microvessel density (MVD) measured 
through CD31 was not recorded. Even though, 
Djordjevica et al. reported an inverse correlation 
between VEGF expression and MVD, which can be 
found in CCRCC [27].
 
In our study, lower VEGF-A expression was 
also associated with an increased risk of renal cancer 
death and recurrence in CCRCC patients. Surgical 
removal of CCRCC with high VEGF-A expression in 
the lower stages, without metastasis, is associated 
with increased cancer-free survival. These 
circumstances explain VEGF-A expression is closely 
linked with better survival. 
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The trend of decreasing levels of VEGF 
expression in advanced tumour stages may indicate 
that angiogenic activity is an early event in tumour 
growth, but during later tumour progression, the role 
of VEGF is less clear. Jacobsen et al. [28] postulate 
that lower VEGF-A expression in higher tumour 
nuclear grade and pathological tumour stage can 
result due to other proliferative and angiogenic factors 
overcoming VEGF-A expression.  Thus, these other 
factors may have a key role in disease progression 
and short survival in patients with metastatic CCRCC. 
The complexities of multiple different growth factors 
are not completely understood, and their role and 
relationship remain important as a subject of future 
investigation in RCC [29]. 
In conclusion, this study demonstrates that 
tumour VEGF-A expression is a valuable prognostic 
indicator of low-grade CCRCC and can be used to 
stratify advanced and metastatic CCRCC patients into 
low-benefit and high-benefit groups. High VEGF-A 
expression patients will benefit from anti-angiogenic 
treatment with VEGF blockers or VEGF receptor 
blockers. On the other hand, low VEGF-A expression 
patients will not benefit from this therapy, and they 
should be treated with alternative medications.
 
Therefore, we recommend that performing 
IHC staining for VEGF-A expression would be very 
useful in the treatment strategy of patients with 
CCRCC. 
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